Prosecution Insights
Last updated: October 02, 2026

Examiner: HOPKINS, SAMANTHA LAKE

Tech Center 1600 • Art Units: 1641 1674 1677 1692

This examiner grants 60% of resolved cases

Analysis

Samantha Lake Hopkins serves in Tech Center 1600 and Art Unit 1641. The examiner has 53 resolved cases. The data indicates an allowance rate of 60.4 percent. This figure provides a metric for assessing the chances of success. The median days to allowance is 1412. This duration represents the typical time required to reach a grant. Applicants should prepare for a prosecution lifecycle matching this timeframe.

The interview lift for Hopkins is 62.3 percent. This exceptionally high statistic shows that interviews are a critical tool for obtaining an allowance. The 62.3 percent interview lift is larger than the 60.4 percent allowance rate. Across the 53 resolved cases, the median days to allowance of 1412 is a primary planning factor. In Art Unit 1641, the interview lift suggests that direct engagement is an essential strategy. This data provides a baseline for success in Tech Center 1600.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

60.4%
Allow Rate
At TC average
80
Total Applications
+62.3%
Interview Lift
1412
Avg Prosecution Days
Based on 53 resolved cases, 2023–2026

Rejection Statute Breakdown

1.8%
§101 Eligibility
16.8%
§102 Novelty
26.1%
§103 Obviousness
33.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18547192 METHODS OF TREATING LUNG CANCER BY ADMINISTERING A PD-1 INHIBITOR Final Rejection Regeneron Pharmaceuticals, Inc.
17244864 METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Final Rejection Regeneron Pharmaceuticals, Inc.
17621746 ANTIGEN BINDING MOLECULES THAT BIND PDGF-B AND PDGF-D AND USES THEREOF Non-Final OA Chugai Seiyaku Kabushiki Kaisha
18021323 LFA-1 SIGNALLING MEDIATOR FOR USE IN CANCER THERAPY Final Rejection Universität Basel
18547594 TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES Non-Final OA THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
18452405 EGFR TARGETING PEPTIDE CONJUGATE Non-Final OA Chapman University

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month